GSK Wins UK Approval for Lynavoy — But Investors Still Want the Bigger Growth Story
Britain’s MHRA approved GSK’s Lynavoy for itching in adults with primary biliary cholangitis, following U.S. clearance in March. The decision comes days after GSK shares fell on investor concerns over first-quarter earnings quality. The approval triggers a $20 million payment in GSK’s licensing deal with Alfasigma, part of an agreement worth up to $690 million.